Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

0.00%

20.5¢ raptor resources limited

A new Beginning..., page-2384

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 2384 Last

Share
Profile

Follow
coolcat1941

125 Posts.

38

04/02/19

20:58

Post #: 37327619
Share

Originally posted by Southoz ↑

Lets see if my nose is right with this US second trial.

I think the results were very poor and RAP will realise that it would now be better off not to apply (and get rejected) for FDA approval.

The US second trial failed to meet the pre-defined end-points that had been set in the first US trial (superiority to 75% PPA+NPA) for any illness. RAP now claims the endpoints are arbitrary but they were set following a pre-submission FDA meeting (in 2016).

The argument for non-inferiority to the accuracy of clinical diagnosis is weak. RAP achieved 70% diagnostic accuracy for three illnesses and claims that 70% is better (or not worse than) than the agreement statistics (66%) between adjudicators in its trial. Perhaps but with one proviso.

There can’t be a scenario in which you drop below the accuracy of clinical diagnosis and get close to 50%. There were a high number of participants (15%) in RAPs second US trial who did not provide analysable data (only 1251 out of 1470). Model a worse-case scenario and assume all these participants would have been wrongly diagnosed by the app. RAPs algorithm accuracy estimates will drop below non-inferiority to clinical diagnosis and (most likely) are not statistically significantly better than chance (50%).

MEB tried exactly this same algorithm non-inferiority to clinical diagnosis argument to the FDA and failed. It too had a high problem with drop outs.

Finally the accuracy estimates presented by RAP include patient (parent) reported symptoms. What exactly does the analysis of cough sounds contribute over and above symptoms? No-one knows. The results presented to the market to date conceals what is supposed to be the whole point of the app (analysis of cough sounds). But the FDA is unlikely to approve an app with an interesting charade - (you have to cough into a smartphone).

We’ll see soon enough whether RAP decide discretion is the better part of valor (abandon the FDA process) or if I should be enrolling in RAPs course for retail investors to better recognise good trial results.

Expand

I am constantly amazed at the uninformed comment coming from those who have no vested interest in RAP. Could you please go to Resapp web site ..research peer review articles published over the last few years before making inane comments. RAP is an artificial intelligence company that uses algorithms to work out results on breath sounds provided into a smart phone. More info..data etc..better it gets. Replaces the middle ear {cochlea] with a subjective device versus a objective device. Please look at results to date of accuracy of AI and algorithms versus human involvement in all types of respiratory involvements .Cough into a phone..cough into your smart watch....Things are happening and RAP at fore front..Suggest you look at Resmed and see what is going on there..May the year of the Pig shine on you

RAP Price at posting: 10.0¢ Sentiment: Hold Disclosure: Held
14 Upvote

1 Great analysis

Reply

Top Stories

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Making money: How many microcaps should be in an investor's portfolio?